Thermo Fisher Scientific Inc. (NYSE:TMO) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totalling 3,769,071 shares, a growth of 47.0% from the July 13th total of 2,564,556 shares. Currently, 0.9% of the company’s stock are sold short. Based on an average daily volume of 1,994,647 shares, the days-to-cover ratio is presently 1.9 days.

A number of research analysts have commented on TMO shares. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 target price on the stock in a research note on Monday, April 30th. ValuEngine downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, June 20th. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $230.00 to $233.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and issued a $300.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 26th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $239.08.

TMO opened at $230.00 on Friday. The stock has a market cap of $93.22 billion, a PE ratio of 24.25, a P/E/G ratio of 1.69 and a beta of 1.13. Thermo Fisher Scientific has a 52-week low of $172.15 and a 52-week high of $236.29. The company has a quick ratio of 1.11, a current ratio of 1.58 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 25th. The medical research company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.12. The company had revenue of $6.08 billion during the quarter, compared to the consensus estimate of $5.90 billion. Thermo Fisher Scientific had a return on equity of 16.28% and a net margin of 10.36%. The firm’s revenue was up 21.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.30 EPS. equities research analysts forecast that Thermo Fisher Scientific will post 10.98 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 15th. Stockholders of record on Monday, September 17th will be paid a dividend of $0.17 per share. The ex-dividend date is Friday, September 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.17%.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $212.00, for a total value of $530,000.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $233.95, for a total value of $11,697,500.00. Following the completion of the transaction, the chief executive officer now owns 320,122 shares in the company, valued at approximately $74,892,541.90. The disclosure for this sale can be found here. Insiders sold 168,050 shares of company stock worth $37,585,029 in the last 90 days. Corporate insiders own 0.49% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. DnB Asset Management AS bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $20,196,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $284,000. Rockefeller Capital Management L.P. lifted its position in shares of Thermo Fisher Scientific by 1.9% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 19,770 shares of the medical research company’s stock worth $4,095,000 after purchasing an additional 375 shares during the last quarter. Welch & Forbes LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $9,933,000. Finally, Providence Capital Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 4.1% during the 1st quarter. Providence Capital Advisors LLC now owns 8,647 shares of the medical research company’s stock worth $1,785,000 after purchasing an additional 338 shares during the last quarter. Institutional investors own 85.69% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Fundamental Analysis

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.